Findings

What do systematic reviews say?

4,815 questions · 6,211 findings · 638 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1,052 · 16.9%GRADE not reported 441 · 7.1%Very low 1,700 · 27.4%Low 1,651 · 26.6%Moderate 1,070 · 17.2%High 297 · 4.8%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Intervention not reported

Haloperidol (2 RCTs; 99 participants) · adults undergoing any type of surgery under general anaesthesia Interventions: antiemetic drugs (monoprophylaxis and combination…

1 finding from 1 review

Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta‐analysis 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 99 participants
Low

Abiraterone + ADT vs ADT only

Time to death from any cause · men with metastatic, hormone‐sensitive prostate cancer

Abiraterone + ADT leads to lower time to death from any cause compared with ADT alone (high certainty).

1 finding from 1 review

Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for… 2020 · Cochrane Headline outcomes only
HR 0.64 [0.56, 0.73]
2 studies · 2201 participants
High

Quality of life (Functional Assessment of Cancer Therapy‐prostate [FACT‐P; range 0 to 156; higher values = better quality of life]) measured at 12 months · men with metastatic, hormone‐sensitive prostate cancer

1 finding from 1 review

Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for… 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 838 participants
Moderate

Abiraterone + ADT vs ADT only

Adverse events grade 3 to 5 Range of · men with metastatic, hormone‐sensitive prostate cancer

Abiraterone + ADT leads to higher grades III to V adverse events (severe and life threatening, as per… compared with ADT alone (high certainty).

1 finding from 1 review

Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for… 2020 · Cochrane Headline outcomes only
RR 1.34 [1.22, 1.47]
1 study · 1199 participants
High

Abiraterone + ADT vs ADT only

Time to death from prostate cancerMedian · men with metastatic, hormone‐sensitive prostate cancer

Abiraterone + ADT probably leads to lower time to death due to prostate cancer measured at a median compared with ADT alone (moderate certainty).

1 finding from 1 review

Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for… 2020 · Cochrane Headline outcomes only
HR 0.58 [0.5, 0.68]
2 studies · 2201 participants
Moderate

Abiraterone + ADT vs ADT only

Time to progression · men with metastatic, hormone‐sensitive prostate cancer

Abiraterone + ADT probably leads to lower time to disease progression measured at a median compared with ADT alone (moderate certainty).

1 finding from 1 review

Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for… 2020 · Cochrane Headline outcomes only
HR 0.35 [0.26, 0.49]
2 studies · 2097 participants
Moderate

Abiraterone + ADT vs ADT only

Discontinued treatment due to adverse events measured at a median · men with metastatic, hormone‐sensitive prostate cancer

Abiraterone + ADT probably leads to higher discontinued treatment due to adverse events measured at a median compared with ADT alone (moderate certainty).

1 finding from 1 review

Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for… 2020 · Cochrane Headline outcomes only
RR 1.5 [1.17, 1.92]
1 study · 1199 participants
Moderate

Intervention not reported

Overall survivala · adult women with symptoms of endometrial cancer

The review found no eligible studies for this question.

1 finding from 1 review

Health education interventions to promote early presentation and referral for women with symptoms of endometrial cancer 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Disease‐free survivalb · adult women with symptoms of endometrial cancer

The review found no eligible studies for this question.

1 finding from 1 review

Health education interventions to promote early presentation and referral for women with symptoms of endometrial cancer 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Delayed referralc · adult women with symptoms of endometrial cancer

The review found no eligible studies for this question.

1 finding from 1 review

Health education interventions to promote early presentation and referral for women with symptoms of endometrial cancer 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Delayed presentationd · adult women with symptoms of endometrial cancer

The review found no eligible studies for this question.

1 finding from 1 review

Health education interventions to promote early presentation and referral for women with symptoms of endometrial cancer 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Referral time (days)e · adult women with symptoms of endometrial cancer

The review found no eligible studies for this question.

1 finding from 1 review

Health education interventions to promote early presentation and referral for women with symptoms of endometrial cancer 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Presentation time (days)f · adult women with symptoms of endometrial cancer

The review found no eligible studies for this question.

1 finding from 1 review

Health education interventions to promote early presentation and referral for women with symptoms of endometrial cancer 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Platinum vs non‐platinum therapy

Overall survival (OS) · women with metastatic triple‐negative breast cancer (mTNBC)

Platinum showed no clear difference in overall survival (OS) compared with non‐platinum regimens (moderate certainty).

1 finding from 1 review

Platinum‐containing regimens for triple‐negative metastatic breast cancer 2020 · Cochrane Headline outcomes only
HR 0.85 [0.73, 1]
6 studies · 958 participants
Moderate

Intervention not reported

Treatment discontinuation due to adverse event (safety population) · women with metastatic triple‐negative breast cancer (mTNBC)

The intervention probably leads to lower treatment discontinuation due to adverse event (safety population) (moderate certainty).

1 finding from 1 review

Platinum‐containing regimens for triple‐negative metastatic breast cancer 2020 · Cochrane Headline outcomes only
RR 0.88
5 studies · 843 participants
Moderate

Platinum vs non‐platinum therapy

Time to progression · women with metastatic triple‐negative breast cancer (mTNBC)

It is very uncertain whether platinum changes progression‐free survival/time to progression (PFS/TTP) compared with non‐platinum regimens (very low certainty).

1 finding from 1 review

Platinum‐containing regimens for triple‐negative metastatic breast cancer 2020 · Cochrane Headline outcomes only
HR 0.77 [0.68, 0.88]
8 studies · 1077 participants
Very low

Platinum vs non‐platinum therapy

Tumour response · women with metastatic triple‐negative breast cancer (mTNBC)

Platinum may leads to higher objective tumour response rate (OTRR) (assessable participants) compared with non‐platinum regimens (low certainty).

1 finding from 1 review

Platinum‐containing regimens for triple‐negative metastatic breast cancer 2020 · Cochrane Headline outcomes only
RR 1.4 [1.22, 1.59]
10 studies · 1205 participants
Low

Intervention not reported

Treatment‐related death (safety population) · women with metastatic triple‐negative breast cancer (mTNBC)

The intervention may leads to higher treatment‐related death (safety population) (low certainty).

1 finding from 1 review

Platinum‐containing regimens for triple‐negative metastatic breast cancer 2020 · Cochrane Headline outcomes only
RR 1.06
5 studies · 843 participants
Low

Intervention not reported

Nausea/vomiting* grade 3 or 4 (safety population) · women with metastatic triple‐negative breast cancer (mTNBC)

The intervention may leads to higher nausea/vomiting* grade 3 or 4 (safety population) (low certainty).

1 finding from 1 review

Platinum‐containing regimens for triple‐negative metastatic breast cancer 2020 · Cochrane Headline outcomes only
RR 4.77
3 studies · 655 participants
Low

Intervention not reported

Nephrotoxicity (safety population) · women with metastatic triple‐negative breast cancer (mTNBC)

The review found no eligible studies for this question.

1 finding from 1 review

Platinum‐containing regimens for triple‐negative metastatic breast cancer 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found